Anti-human melanoma effect of Fe(III)-containing wells-dawson nanocluster in vitro
Само за регистроване кориснике
2024
Аутори
Čolović, MirjanaKorićanac, Lela
Žakula, Jelena
Savić, Nada
Parac-Vogt, Tatjana
Krstić, Danijela
Конференцијски прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
The aim of this study was to in vitro assess the anti-tumor potential of Fe(III)-substituted monolacunary Wells-Dawson polyoxotungstate, K7[FeIII(α2-P2W17O61)(H2O)] (FeWD) against human melanoma A375 cells. A375 cells were treated in vitro with FeWD in the concentration range of 0.001-1 mM, for 24, 48, and 72 hours. FeWD decreased A375 cell viability in a dose- and time-dependent manner. IC50 values (in mM), as a marker of the cytotoxic potency of FeWD, were obtained as follows: 1, 0.58, and 0.51, for 24-, 48-, and 72-hour exposure, respectively. However, in comparison with cisplatin as a gold standard in cancer chemotherapy, which was used as a positive control, IC50 values (in mM) were significantly higher than those obtained for cisplatin (0.09, 0.07, and 0.043, for 24, 48, and 72 hours, respectively). For this reason, the studied FeWD polyoxometalate could not be considered a superior anti-cancer candidate compared to the standard chemotherapeutic.
Кључне речи:
A375 cells / anti-tumor metallodrugs / Fe(III)-substituted polyoxometalate / in vitro cytotoxicity / Wells-DawsonИзвор:
International Multidisciplinary Conference "Challenges of Contemporary Higher Education" - CCHE 2024 : Book of proceedings, 2024, 2, 24-27Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200017 (Универзитет у Београду, Институт за нуклеарне науке Винча, Београд-Винча) (RS-MESTD-inst-2020-200017)
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200110 (Универзитет у Београду, Медицински факултет) (RS-MESTD-inst-2020-200110)
- POMCACT - In Vitro and in Vivo Evaluation of Novel Polyoxometalate Based Contrast Agents for Micro Computed Tomography (RS-ScienceFundRS-Dijaspora-6526393)
Напомена:
- CCHE 2024 : Jan 29 - Feb 02, 2024, Kopaonik, Serbia.
Колекције
Институција/група
VinčaTY - CONF AU - Čolović, Mirjana AU - Korićanac, Lela AU - Žakula, Jelena AU - Savić, Nada AU - Parac-Vogt, Tatjana AU - Krstić, Danijela PY - 2024 UR - https://vinar.vin.bg.ac.rs/handle/123456789/12944 AB - The aim of this study was to in vitro assess the anti-tumor potential of Fe(III)-substituted monolacunary Wells-Dawson polyoxotungstate, K7[FeIII(α2-P2W17O61)(H2O)] (FeWD) against human melanoma A375 cells. A375 cells were treated in vitro with FeWD in the concentration range of 0.001-1 mM, for 24, 48, and 72 hours. FeWD decreased A375 cell viability in a dose- and time-dependent manner. IC50 values (in mM), as a marker of the cytotoxic potency of FeWD, were obtained as follows: 1, 0.58, and 0.51, for 24-, 48-, and 72-hour exposure, respectively. However, in comparison with cisplatin as a gold standard in cancer chemotherapy, which was used as a positive control, IC50 values (in mM) were significantly higher than those obtained for cisplatin (0.09, 0.07, and 0.043, for 24, 48, and 72 hours, respectively). For this reason, the studied FeWD polyoxometalate could not be considered a superior anti-cancer candidate compared to the standard chemotherapeutic. C3 - International Multidisciplinary Conference "Challenges of Contemporary Higher Education" - CCHE 2024 : Book of proceedings T1 - Anti-human melanoma effect of Fe(III)-containing wells-dawson nanocluster in vitro VL - 2 SP - 24 EP - 27 UR - https://hdl.handle.net/21.15107/rcub_vinar_12944 ER -
@conference{ author = "Čolović, Mirjana and Korićanac, Lela and Žakula, Jelena and Savić, Nada and Parac-Vogt, Tatjana and Krstić, Danijela", year = "2024", abstract = "The aim of this study was to in vitro assess the anti-tumor potential of Fe(III)-substituted monolacunary Wells-Dawson polyoxotungstate, K7[FeIII(α2-P2W17O61)(H2O)] (FeWD) against human melanoma A375 cells. A375 cells were treated in vitro with FeWD in the concentration range of 0.001-1 mM, for 24, 48, and 72 hours. FeWD decreased A375 cell viability in a dose- and time-dependent manner. IC50 values (in mM), as a marker of the cytotoxic potency of FeWD, were obtained as follows: 1, 0.58, and 0.51, for 24-, 48-, and 72-hour exposure, respectively. However, in comparison with cisplatin as a gold standard in cancer chemotherapy, which was used as a positive control, IC50 values (in mM) were significantly higher than those obtained for cisplatin (0.09, 0.07, and 0.043, for 24, 48, and 72 hours, respectively). For this reason, the studied FeWD polyoxometalate could not be considered a superior anti-cancer candidate compared to the standard chemotherapeutic.", journal = "International Multidisciplinary Conference "Challenges of Contemporary Higher Education" - CCHE 2024 : Book of proceedings", title = "Anti-human melanoma effect of Fe(III)-containing wells-dawson nanocluster in vitro", volume = "2", pages = "24-27", url = "https://hdl.handle.net/21.15107/rcub_vinar_12944" }
Čolović, M., Korićanac, L., Žakula, J., Savić, N., Parac-Vogt, T.,& Krstić, D.. (2024). Anti-human melanoma effect of Fe(III)-containing wells-dawson nanocluster in vitro. in International Multidisciplinary Conference "Challenges of Contemporary Higher Education" - CCHE 2024 : Book of proceedings, 2, 24-27. https://hdl.handle.net/21.15107/rcub_vinar_12944
Čolović M, Korićanac L, Žakula J, Savić N, Parac-Vogt T, Krstić D. Anti-human melanoma effect of Fe(III)-containing wells-dawson nanocluster in vitro. in International Multidisciplinary Conference "Challenges of Contemporary Higher Education" - CCHE 2024 : Book of proceedings. 2024;2:24-27. https://hdl.handle.net/21.15107/rcub_vinar_12944 .
Čolović, Mirjana, Korićanac, Lela, Žakula, Jelena, Savić, Nada, Parac-Vogt, Tatjana, Krstić, Danijela, "Anti-human melanoma effect of Fe(III)-containing wells-dawson nanocluster in vitro" in International Multidisciplinary Conference "Challenges of Contemporary Higher Education" - CCHE 2024 : Book of proceedings, 2 (2024):24-27, https://hdl.handle.net/21.15107/rcub_vinar_12944 .